尿液脑啡肽酶用于心脏手术后急性肾损伤的早期检测:一项前瞻性观察研究
该前瞻性观察性队列研究纳入96例择期体外循环心脏手术患者,评估尿液脑啡肽酶早期检测心脏手术后急性肾损伤(AKI)的价值。结果显示AKI发生率为27%(n=26),AKI组术后第1天及手术结束时尿液脑啡肽酶中位数均显著高于非AKI组,其检测早期AKI的曲线下面积为0.77(95%CI 0.65–0.90),提示尿液脑啡肽酶可能作为早期检测AKI的生物标志物。
要点
- 心脏手术后AKI发生率为27%(n=26/96)。
- AKI组术后第1天尿液脑啡肽酶中位数4.0 ng/ml显著高于非AKI组2.0 ng/ml(P=0.0246)。
- 尿液脑啡肽酶检测早期AKI的AUC为0.77(95%CI 0.65–0.90)。
核心结论
- 尿液脑啡肽酶有潜力作为心脏手术后急性肾损伤早期检测的生物标志物,其区分能力与近期研究的AKI生物标志物相当。
研究设计与样本
- 前瞻性观察性队列研究,在奥地利三级转诊中心纳入96例接受择期体外循环心脏手术的患者。
主要发现
- AKI发生率为27%(n=26)。
- 术后第1天尿液脑啡肽酶中位数AKI组为4.0 ng/ml(IQR 2–6.25),非AKI组为2.0 ng/ml(IQR 1.0–4.5),P=0.0246。
- 手术结束时尿液脑啡肽酶中位数AKI组为5.0 ng/ml(IQR 2.0–9.0),非AKI组为2.0 ng/ml(IQR 1.0–4.0),P=0.0055。
- 尿液脑啡肽酶检测早期AKI的曲线下面积为0.77(95%CI 0.65–0.90)。
关键数值与推荐
- AKI定义采用肾脏疾病改善全球预后组织(KDIGO)标准。
临床怎么用
- 对于体外循环心脏手术患者,可考虑监测尿液脑啡肽酶以辅助早期识别AKI高风险患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute kidney injury (AKI) predicts adverse outcomes after cardiac surgery. The accuracy of using changes in serum creatinine for diagnosis and grading of AKI is limited in the peri-operative cardiac surgical setting and AKI may be underdiagnosed due to haemodilution from cardiopulmonary bypass priming and the need for intra-operative and postoperative volume resuscitation. OBJECTIVES: To determine whether the urinary biomarker neprilysin can be used as a marker for the early detection of AKI after cardiac surgery. DESIGN: Prospective, observational cohort study. SETTING: Austrian tertiary referral centre. PATIENTS: 96 Patients undergoing elective cardiac surgery with cardiopulmonary bypass. MAIN OUTCOME MEASURES: Differences and discriminatory power of neprilysin levels early after cardiac surgery and on postoperative day 1 between patients with or without AKI, as defined by the Kidney Disease Improving Global Outcomes Group. RESULTS: AKI was found in 27% (n=26). The median neprilysin levels on postoperative day 1 were significantly higher in the AKI than in the non-AKI group, 4.0 [interquartile range (IQR): 2 to 6.25] vs. 2.0 ng ml [IQR: 1.0 to 4.5], P = 0.0246, respectively. In addition, the median neprilysin levels at the end of surgery were significantly different between both groups, 5.0 [IQR: 2.0 to 9.0] vs. 2.0 ng ml [IQR: 1.0 to 4.0], P = 0.0055, respectively. The discriminatory power of neprilysin for detecting early AKI corresponded to an area under the curve of 0.77 (95% confidence interval, 0.65 to 0.90). CONCLUSION: Urinary neprilysin has potential as a biomarker for the early detection of AKI after cardiac surgery and has comparable discriminatory power to recently studied AKI biomarkers. TRIAL REGISTRATION: The trial was registered at ClinicalTrials.gov (NCT03854825, https://clinicaltrials.gov/ct2/show/NCT03854825).
引用
- Bernardi MH, Wagner L, Ryz S, et al. Urinary neprilysin for early detection of acute kidney injury after cardiac surgery: A prospective observational study. Eur J Anaesthesiol. 2021. PMID: 32941200. doi:10.1097/EJA.0000000000001321
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。